Table 1.
Baseline Demographic and Clinical Characteristics
| Parameter | RA Patients (n=20) |
|---|---|
| Age, y | 53 (46, 62) |
| RA disease duration, y | 12 (6.5 to 14.75) |
| Female, n (%) | 19 (95) |
| Race | |
| Hispanic, n (%) | 17 (85) |
| Black, n (%) | 1 (5) |
| Other, n (%) | 2 (10) |
| Rheumatoid factor, n (%) | 17 (85) |
| Anti‐CCP positive, n (%) | 17 (89) |
| Radiographic changes, n (%) | 14 (70) |
| Prior CAD, n (%) | 1 (5) |
| Hypertension, n (%) | 8 (40) |
| Hyperlipidemia, n (%) | 5 (25) |
| Diabetes mellitus, n (%) | 4 (20) |
| Current smoking, n (%) | 5 (25) |
| Ever smoked, n (%) | 6 (30) |
| Family history of CAD, n (%) | 3 (15) |
| ASA/NSAID, n (%) | 12 (60) |
| Taking prednisone, n (%) | 16 (80) |
| Taking methotrexate, n (%) | 12 (60) |
| BMI, kg/m2 | 33.5 (27.6, 35.8) |
| DAS28‐ESR | 6.6 (6.1, 7.1) |
| DAS28‐CRP | 6.0 (5.2, 6.6) |
| Swollen joint count | 13.3 (10.0, 17.0) |
| Tender joint count | 12.8 (7.0, 16.0) |
| DMARD use, % | 18 (90) |
Values are represented as medians (interquartile range), unless otherwise noted. Anti‐CCP positive indicates anti‐cyclic citrullinated peptide antibodies; ASA/NSAID, use of aspirin or non‐steroidal anti‐inflammatory drugs; BMI, body mass index; CAD, coronary artery disease; DAS28‐CRP, disease activity score 28‐joints based on C‐reactive protein; DAS28‐ESR, disease activity score 28‐joints based on erythrocyte sedimentation rate; DMARD, disease‐modifying antirheumatic drugs; RA, rheumatoid arthritis.